Citadel Advisors
ACHV icon

Citadel Advisors’s Achieve Life Sciences ACHV Stock Holding History

Citadel Advisors’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,000
Closed -$84.5K – 12866
2025
Q4 		$84.5K Sell
17,000
-14,100
-45% -$61.5K ﹤0.01% 11761
2025
Q3 		$98K Buy
31,100
+3,600
+13% +$9.88K ﹤0.01% 11863
2025
Q2 		$62.1K Buy
27,500
+25,600
+1,347% +$72.9K ﹤0.01% 11661
2025
Q1 		$5.07K Buy
1,900
+1,400
+280% +$4.35K ﹤0.01% 13842
2024
Q4 		$1.76K Sell
500
-3,200
-86% -$14.5K ﹤0.01% 14151
2024
Q3 		$17.5K Sell
3,700
-900
-20% -$4.11K ﹤0.01% 12880
2024
Q2 		$21.6K Sell
4,600
-2,100
-31% -$10.1K ﹤0.01% 12560
2024
Q1 		$30.5K Buy
+6,700
New +$29.7K ﹤0.01% 12687
2023
Q4 		– Sell
-21,700
Closed -$93.3K – 14169
2023
Q3 		$93.3K Buy
21,700
+7,200
+50% +$36.3K ﹤0.01% 10988
2023
Q2 		$75.3K Buy
14,500
+10,500
+263% +$73.6K ﹤0.01% 11308
2023
Q1 		$27.2K Buy
4,000
+1,000
+33% +$4.75K ﹤0.01% 12822
2022
Q4 		$7.41K Buy
+3,000
New +$7.7K ﹤0.01% 13825

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors's ACHV Position: Q2 2026 in Review

Citadel Advisors opened a new position in Achieve Life Sciences (ACHV) in Q2 2026: 123,129 shares worth $804K. The stake represents ﹤0.01% of the portfolio and ranks #8750 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ACHV as recently as Q2 2025.

Citadel Advisors first reported a position in ACHV in Q1 2015 and has held it in 23 quarters since. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • Citadel Advisors held 123,129 shares of Achieve Life Sciences worth $804K as of Q2 2026.
  • Achieve Life Sciences was a new Citadel Advisors position in Q2 2026.
  • Achieve Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8750 holding.
  • Citadel Advisors first reported a position in Achieve Life Sciences in Q1 2015 and has held it in 23 quarters since.
  • 111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.